 | | Vol. 9.46 – 24 November, 2021 |
| |
|
|
| Scientists found that skin CD4+ tissue-resident memory T cells were depleted after HIV infection and replenished only upon early antiretroviral therapy initiation.
[Immunity] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Lung autopsy samples from 18 patients with fatal COVID-19, with symptom onset-to-death times ranging from 3 to 47 days, and antemortem plasma samples from 6 of these cases were evaluated using deep sequencing of SARS-CoV-2 RNA, multiplex plasma protein measurements, and pulmonary gene expression and imaging analyses.
[Science Translational Medicine] |
|
|
|
| Analysis of the gene expression profile from COVID-19 patients as well as SARS-CoV-2 infected epithelial cell lines revealed that the induction of the MHC class I pathway was inhibited by SARS-CoV-2 infection.
[Nature Communications] |
|
|
|
| Researchers showed that B38-CAP, an ACE2-like enzyme, was protective against SARS-CoV-2-induced lung injury.
[Nature Communications] |
|
|
|
| The authors analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluated efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments.
[Journal of Biomedical Science] |
|
|
|
| Analysis of eight single-cells RNA-seq datasets from peripheral blood mononuclear cells, nasopharyngeal samples and Broncho alveolar lavage fluid, revealed significantly reduced mtDNA gene expression especially in immune system cells from patients.
[iScience] |
|
|
|
| Scientists used sialodacryoadenitis virus in rats to model the extent to which immune protection afforded by prior natural infection via high risk or low risk exposure, or by vaccination, influenced viral shedding and transmission on re-exposure.
[PLoS One] |
|
|
|
| The authors reported a severe case of neonatal COVID-19 requiring intensive care and mechanical ventilation, further complicated by a multidrug resistant Enterobacter asburiae super-infection.
[Journal of Medical Virology] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Investigators determined whether HIV-1 infection caused Alzheimer’s Disease-like pathologies in an HIV/AIDS humanized mouse model, and whether the CCR5 antagonist maraviroc altered HIV-induced pathologies.
[Molecular Neurodegeneration] |
|
|
|
| Scientists conducted a genome-wide quantitative trait locus analysis to probe functionally relevant genetic variants linked to levels of cell-associated HIV-1 DNA, CA HIV-1 RNA, and RNA:DNA ratio in CD4+ T cells isolated from blood from a cohort of 207 people living with HIV-1 on long-term suppressive antiretroviral treatment
[BMC Medicine] |
|
|
|
| Parasitemia was measured using qPCR; immunogenicity was determined using standard assays. Parasites were rescued into culture for in vitro analyses.
[BMC Medicine] |
|
|
|
| The authors demonstrated that the delayed fractional dose maintained monocyte phagocytosis and NK activation mediated by NANP6-specific antibodies, key correlates of protection for the RTS,S/AS01 doses regimen.
[Med] |
|
|
|
|
| Investigators highlight emerging technologies and infection models that recently promoted opportunities in cellular microbiology.
[Nature Communications] |
|
|
|
| Scientists summarize current insights into the mechanisms of macrophage-mediated host defense and repair during helminth infection and highlight recent progress on the immune regulatory crosstalk between macrophages and helminth parasites.
[Seminars in Immunology] |
|
|
|
|
| Pulmonem, Inc. and the Research Institute of the McGill University Health Centre today announced that they have successfully started recruiting US-based patients for the Phase III Clinical Trial of the promising COVID-19 therapeutic drug PULM-001.
[Pulmonem, Inc.] |
|
|
|
| Todos Medical, Ltd. together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., announced an update regarding the ongoing clinical development of Tollovir®, a oral antiviral 3CL protease inhibitor & anti-cytokine therapeutic candidate for the treatment of COVID-19.
[Todos Medical, Ltd.] |
|
|
|
|
| November 28 – December 1, 2021
Edinburgh, Scotland, United Kingdom |
|
|
|
|
|
| | University Medical Center Freiburg – Freiburg, Germany |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | The Henry M. Jackson Foundation for the Advancement of Military Medicine – Silver Spring, Mayland, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | Lund University РMalm̦, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
